A detailed history of Black Rock Inc. transactions in Immuneering Corp stock. As of the latest transaction made, Black Rock Inc. holds 533,364 shares of IMRX stock, worth $912,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares
533,364
Previous 1,377,120 61.27%
Holding current value
$912,052
Previous $3.98 Million 82.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.28 - $2.75 $1.08 Million - $2.32 Million
-843,756 Reduced 61.27%
533,364 $682,000
Q1 2024

May 10, 2024

SELL
$1.91 - $7.32 $1.38 Million - $5.27 Million
-720,286 Reduced 34.34%
1,377,120 $3.98 Million
Q4 2023

Feb 13, 2024

SELL
$4.84 - $8.44 $2.01 Million - $3.5 Million
-414,612 Reduced 16.51%
2,097,406 $15.4 Million
Q3 2023

Nov 13, 2023

BUY
$7.21 - $10.68 $637,075 - $943,684
88,360 Added 3.65%
2,512,018 $19.3 Million
Q2 2023

Aug 11, 2023

BUY
$6.49 - $13.36 $7.03 Million - $14.5 Million
1,083,465 Added 80.84%
2,423,658 $24.6 Million
Q1 2023

May 12, 2023

SELL
$3.78 - $10.38 $30,961 - $85,022
-8,191 Reduced 0.61%
1,340,193 $13 Million
Q4 2022

Feb 13, 2023

SELL
$4.09 - $15.0 $309,408 - $1.13 Million
-75,650 Reduced 5.31%
1,348,384 $6.54 Million
Q3 2022

Nov 14, 2022

BUY
$5.0 - $14.32 $336,820 - $964,652
67,364 Added 4.97%
1,424,034 $20.4 Million
Q2 2022

Aug 12, 2022

SELL
$3.89 - $7.81 $2.98 Million - $5.99 Million
-766,704 Reduced 36.11%
1,356,670 $7.34 Million
Q1 2022

May 12, 2022

BUY
$6.47 - $16.99 $2.63 Million - $6.92 Million
407,204 Added 23.73%
2,123,374 $13.7 Million
Q4 2021

Feb 10, 2022

BUY
$16.12 - $31.02 $3.09 Million - $5.95 Million
191,796 Added 12.58%
1,716,170 $27.8 Million
Q3 2021

Nov 09, 2021

BUY
$17.0 - $32.84 $25.9 Million - $50.1 Million
1,524,374 New
1,524,374 $40.5 Million

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $45.1M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.